Erbitax Approved For Additional Indication Of Head And Neck Cancers
This article was originally published in PharmAsia News
Executive Summary
Merck Serono received approval to add head and neck cancer as additional indications for Erbitux (cetuximab) in Japan, the company announced Dec. 21.